An investigation for investors in NASDAQ:NVLS shares over potential securities laws violations by Nivalis Therapeutics Inc was announced and NASDAQ:NVLS stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/07/2016 -- An investigation on behalf of investors of Nivalis Therapeutics Inc (NASDAQ:NVLS) shares over potential securities laws violations by Nivalis Therapeutics Inc in connection certain financial statements was announced.
Investors who purchased shares of Nivalis Therapeutics Inc (NASDAQ:NVLS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Nivalis Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On November 28, 2016, Nivalis Therapeutics Inc announced that its Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, in comparison to placebo.
Shares of Nivalis Therapeutics Inc (NASDAQ:NVLS) declined on December 5, 2016, to as low as $2.02 per share.
Those who purchased shares of Nivalis Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com